Last Updated: September 24, 2026

Details for New Drug Application (NDA): 201532

✉ Email this page to a colleague

NDA 201532 describes HALAVEN, which is a drug marketed by Eisai Inc and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the HALAVEN profile page.

The generic ingredient in HALAVEN is eribulin mesylate. There is one drug master file entry for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the eribulin mesylate profile page.

Summary for 201532

Tradename:	HALAVEN
Applicant:	Eisai Inc
Ingredient:	eribulin mesylate
Patents:	1

Pharmacology for NDA: 201532

Physiological Effect	Microtubule Inhibition

Suppliers and Packaging for NDA: 201532

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532	NDA	BSP Pharmaceuticals SpA	43624-002	43624-002-01	100 VIAL in 1 TRAY (43624-002-01) / 2 mL in 1 VIAL
HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532	NDA	Eisai Inc.	62856-389	62856-389-01	1 VIAL, SINGLE-DOSE in 1 CARTON (62856-389-01) / 2 mL in 1 VIAL, SINGLE-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;INTRAVENOUS			Strength	1MG/2ML (0.5MG/ML)
Approval Date:	Nov 15, 2010	TE:	AP	RLD:	Yes
Regulatory Exclusivity Expiration:	Mar 13, 2026
Regulatory Exclusivity Use:	PEDIATRIC EXCLUSIVITY
Regulatory Exclusivity Expiration:	Sep 13, 2025
Regulatory Exclusivity Use:	REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDIES E7389-G000-223 AND E7389-G000-213, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
Patent:	⤷ Start Trial	Patent Expiration:	Jul 8, 2027	Product Flag?		Substance Flag?		Delist Request?	Y

Expired US Patents for NDA 201532

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eisai Inc	HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532-001	Nov 15, 2010	⤷ Start Trial	⤷ Start Trial
Eisai Inc	HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532-001	Nov 15, 2010	⤷ Start Trial	⤷ Start Trial
Eisai Inc	HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532-001	Nov 15, 2010	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.